• Antigenic-SARS-CoV-2-monitoring-Joint-ECDC-WHO-report-June-2022
• Balancing in Competition Law
• Eudravigilance e Rete Nazionale di Farmacovigilanza_ AIFA incontra gli operatori del settore per presentare le novità europee e italiane – 2017-11-13
• Il private enforcement delle regole sugli aiuti di Stato nella giurisprudenza italiana
• Abusive pricing in an IP licensing context_
• AGCM e imposizione di prezzi eccessivi ed iniqui per i farmaci_ il caso Aspen
• Aiuti di Stato e stato di emergenza tra solidarietà e condizionalità_
• COMPETITION ISSUES IN THE DISTRIBUTION OF PHARMACEUTICALS Contribution from Ms Sabine Vogler -DAF-COMP-GF(2014)6
• EFPIA CODE OF PRACTICE
• Excessive Prices in Pharmaceutical Markets Background Note by the Secretariat – DAF-COMP(2018)12.en
• Executive Summary of the Discussion on Competition and Generic Pharmaceuticals – DAF-COMP-M(2014)2-ANN6-FINAL
• Guide to information on human medicines evaluated by EMA
• Health systems governance in Europe
• Il diritto alla salute, una prospettiva di diritto comparato
• l complesso bilanciamento tra le norme della concorrenza dell’Unione europea e la disciplina regolatoria del settore farmaceutico_ il caso Avastin-Lucentis
• L’Accordo su un tribunale unificato dei brevetti, il recesso del Regno Unito e la decisione della Corte Costituzionale tedesca sulla nullità dell’Atto di ratifica
• L’evoluzione dei diritti e delle libertà fondamentali nel settore dei media. Diritto dell’Unione europea e orientamenti giurisprudenziali_
• La tutela dei dati personali nella giurisprudenza della Corte di giustizia
• La tutela del consumatore nell’ applicazione delle norme di concorrenza dell’Unione
• Norme legislative che regolamentano e differenziano l’utilizzo di farmaci
• Overview-of-COVID-19-vaccination-strategies-deployment-plans-in-the-EU-EEA
• Personalized Pricing, Competition and Welfare
• Pharmaceutical markets and antitrust_ selected issues on compliance and private enforcement
• Potential Competition in EU Law
• Rebates after the General Court’s Intel Judgment
• Standard-essential patents and incentives for innovation
• The Concept of Dominance in EC Competition Law
• The covid-19 vaccine race_ intellectual property, collaboration(s), nationalism and misinformation
• THE ETERNAL STRUGGLE BETWEEN IP RIGHTS AND ANTITRUST LAW IN LIGHT OF THE HUAWEI CASE
• The European regulatory system for medicines A consistent approach to medicines regulation across the European Union
• The future of refusals to deal and margin squeezes in the face of sector-specific regulation
• The legal and regulatory framework for community pharmacies in the WHO European Region
• The necessary limits to the control of “excessive” prices by competition authorities – A view from Europe
• The TRIPS Intellectual Property Waiver Proposal_ Creating the Right Incentives in Patent Law and Politics to end the COVID-19 Pandemic
• To protect or (not) to protect_ definitional complexities concerning personal (and non-personal) data within the EU
• When Are Excessive Prices Unfair_ -CCP Working Paper 10-4
• WHO – World Health Statistics 2022
• Big Data e concorrenza all’interno del settore farmaceutico
• COMPETITION ISSUES IN THE DISTRIBUTION OF PHARMACEUTICALS Contribution from Farasat A.S. Bokhari and Franco Mariuzzo – DAF-COMP-GF(2014)4
• COMPETITION ISSUES IN THE DISTRIBUTION OF PHARMACEUTICALS Contribution from Mr Panos Kanavos- DAF-COMP-GF(2014)8